TB-500

Overview

Origin and why it was developed

The story of TB-500 begins in the thymus — a small immune organ beneath the breastbone, large in children and gradually shrinking in adults. In the 1960s, Allan Goldstein (then still a young immunologist) was searching there for the proteins responsible for the development of T-cells. He found a whole family of them, named them thymic fractions, and later thymosins.

One of them was Thymosin β-4 (Tβ4). Goldstein noticed something unusual — Tβ4 was not only in the thymus. It was practically everywhere in the body: in muscles, in liver, in cardiac cells, in platelets, in macrophages. And there was a lot of it — Tβ4 is among the most abundant proteins in mammalian cells, with concentrations reaching hundreds of micrograms per gram of tissue.

The question therefore was: why does the body maintain such a high pool of this molecule? The answer came only in the 1990s — Tβ4 is the main regulator of actin, the most important structural protein of the cellular skeleton.

What “TB-500” actually is as a molecule

Here an honest distinction is important. In the academic literature there are two interpretations of the name “TB-500”:

1. The original academic definition: TB-500 = the 7-amino-acid active fragment of Tβ4 (Ac-LKKTETQ, position 17 to 23 of the full molecule). This fragment contains the active actin-binding site and in some studies reproduces the main regenerative effects of the full molecule.

2. Commercial practice: “TB-500” is used as a synonym for the full 44-amino-acid Thymosin β-4. Most peptide suppliers (including Molequa) sell the full Tβ4 under this name, because it is pharmacologically more relevant and corresponds to the molecule used in clinical trials (REGENERATE-1, TB4-Eye).

In this product Molequa supplies the full Thymosin β-4 (44 aa, MW 4963 Da). This is the standard in the research community. If you are looking for the pure 7-amino-acid fragment, contact us directly — we also do custom syntheses.

Mechanism of action — what it does at the cellular level

The main role: actin regulator

Actin is the most important structural protein in the cell. Imagine it as Lego bricks — when they are free, they are small monomers (G-actin). When they join, they form long chains (F-actin) that make up the cellular skeleton (cytoskeleton). This skeleton holds the shape of the cell, but dynamically rearranges itself whenever the cell needs to migrate, divide or change shape.

Tβ4 is the “storage molecule” for G-actin. Imagine it as a shelf in a warehouse of Lego bricks. It holds the monomers ready until the cell receives the signal: “Now! Build!” At that moment Tβ4 releases the G-actin, which joins the F-actin chains, and the cell can migrate or change shape.

This is why Tβ4 has an effect on every process that requires cell movement:

• Wound healing (fibroblasts migrate into the wound)
• Vessel formation (endothelial cells migrate and build new vessels)
• Immunity (macrophages, neutrophils move toward inflammation)
• Embryonic development (cells move to their positions)
• Cardiac healing after infarction (cardiomyocytes + epicardial cells)

Induction of angiogenesis (formation of new vessels)

Tβ4 induces expression of VEGF (Vascular Endothelial Growth Factor), the main growth factor for new vessels. At the same time it mobilizes endothelial progenitor cells (EPCs) from the bone marrow — these are “semi-finished” future endothelial cells that travel via the arteries to sites of damage.

Imagine it like this: when damage occurs somewhere, the tissue sends out an SOS signal. The body responds by calling in two teams of repair workers: residents (local cells) and an external team (EPCs from bone marrow). Tβ4 mobilizes both teams and provides them with the necessary “tools” (actin for migration).

Anti-inflammatory effect via NF-κB

NF-κB (Nuclear Factor kappa B) is the main switch of the inflammatory response in cells. When it is on for too long, chronic inflammation develops that damages tissue instead of healing it. Tβ4 modulates NF-κB (does not fully switch it off!), thereby dampening excess inflammation and protecting cells from secondary damage.

In cardiac models after infarction this effect is critical — most of the heart damage is caused by secondary inflammation, not the infarction itself.

Anti-apoptotic effect

Apoptosis is “programmed cell death”. In damaged tissues even cells that could survive often die — Tβ4 protects them via activation of the integrin-linked kinase (ILK) pathway and stabilization of the mitochondrial membrane.

For the heart after infarction this is again critical — more surviving cardiomyocytes = a smaller scar = better contractile function.

Mobilization of stem cells

Tβ4 chemo-attracts (draws in) stem cells and progenitor cells to sites of damage. In cardiac models (Smart et al., Nature 2007) Tβ4 mobilized epicardial progenitor cells — a population that is normally “dormant” in adults — and stimulated their differentiation into new cardiomyocytes and vascular cells.

This is revolutionary, because the adult heart practically does not regenerate. Tβ4 showed that, potentially, it can.

What this means in practice: TB-500 is not just “passive building material”. It is a multi-functional regulator that simultaneously (1) enables cell movement via actin, (2) draws stem cells to the site of damage, (3) protects existing cells from inflammation and death, and (4) supports the formation of new vessels. That is precisely why it became the second half of the canonical “regenerative combination” with BPC-157.

Researched applications

In the published preclinical and clinical literature the effects of Tβ4 / TB-500 are documented in the following areas:

• Tendon and ligament healing, Achilles tendon, tendinopathy models, combination with BPC-157
• Muscle injuries and regeneration, laceration models, contusions, skeletal muscle
• Cardiac regeneration, animal models of myocardial infarction, clinical trials (REGENERATE-1)
• Skin wound healing, diabetic ulcers, burns, chronic ulcerations
• Ophthalmological applications, dry eye (Tβ4 ophthalmic solution, clinical trials)
• Neurogenesis and nervous tissue regeneration, preclinical models of stroke (CVA)
• Hepatic fibrosis, models of chronic liver injury
• Hair follicles, preclinical models of alopecia
• Pulmonary fibrosis, preclinical models of IPF

Science & studies

4.1 Key publications

Goldstein A.L., Hannappel E., Sosne G., Kleinman H.K. (2012). Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 12(1):37 to 51. Comprehensive review by the “mother” of the molecule.

Crockford D., Turjman N., Allan C., Angel J. (2010). Thymosin β4: structure, function, and biological properties supporting current and future clinical applications. Ann N Y Acad Sci. 1194:179 to 189. Standard reference review for Tβ4.

Smart N., Risebro C.A., Melville A.A.D., et al. (2007). Thymosin β4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 445(7124):177 to 182. Landmark Nature publication on cardiac regeneration.

Bock-Marquette I., Saxena A., White M.D., DiMaio J.M., Srivastava D. (2004). Thymosin β4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 432(7016):466 to 472. Mechanistic Nature publication on the anti-apoptotic effect in the heart.

Ruff D., Crockford D., Girardi G., Zhang Y. (2010). A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin β4 in healthy volunteers. Ann N Y Acad Sci. 1194:223 to 229. Clinical safety data in humans.

Sosne G., Qiu P., Goldstein A.L., Wheater M. (2010). Biological activities of thymosin β4 defined by active sites in short peptide sequences. FASEB J. 24(7):2144 to 2151. Mapping of active sequences within Tβ4 — context for the “TB-500 fragment vs full peptide” debate.

4.2 Detailed expandable studies

▸ Study 1: Skin wound healing in mice

Citation: Malinda K.M., Sidhu G.S., Mani H., et al. Thymosin β4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364 to 368.

What they did: A classic wound-healing study. Mice were given standardized skin wounds (4 mm punch biopsy) and Tβ4 was administered either topically (directly onto the wound) or systemically (intraperitoneally). They monitored the rate of wound contraction, re-epithelialization and formation of granulation tissue.

What they found:

• Tβ4 accelerated wound contraction by 42 % vs control
• Re-epithelialization (closure of the surface layer of skin) was faster by 11 days on average
• Histologically: denser capillary network, better collagen organization
• Topical and systemic administration worked comparably

Why it matters: This was one of the first studies to demonstrate Tβ4 effects outside the immune system. It opened a whole wave of wound-healing research and led directly to the development of the TB4-Wound clinical program for diabetic ulcers.

▸ Study 2: Cardiac regeneration after infarction (Nature 2004)

Citation: Bock-Marquette I., Saxena A., White M.D., DiMaio J.M., Srivastava D. Thymosin β4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466 to 472.

What they did: A mouse model of myocardial infarction (MI). They ligated a coronary artery, which produced a precisely defined infarction. Half of the mice received Tβ4 systemically (intraperitoneally, 150 µg). They evaluated scar size, contractile heart function (echocardiography) and markers of cardiomyocyte survival.

What they found:

• Tβ4 reduced scar volume by 25 % vs control
• Ejection fraction (a parameter of the heart’s pumping function) was better by 9 percentage points
• Mechanistically: activation of ILK (integrin-linked kinase) → anti-apoptotic signal → fewer cardiomyocytes died after the infarction
• Mobilization of epicardial cells into the infarct area

Why it matters: This is one of the two landmark Nature publications on Tβ4 in cardiology. It opened the concept that the adult heart has regenerative capacity that is merely “dormant”, and that Tβ4 can wake it up. It led directly to the REGENERATE-1 clinical program.

▸ Study 3: Mobilization of epicardial progenitors (Nature 2007)

Citation: Smart N., Risebro C.A., Melville A.A.D., et al. Thymosin β4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007;445(7124):177 to 182.

What they did: A continuation of the Bock-Marquette line. A mouse model of infarction, but with detailed tracking of the fate of specific cell populations using genetic labeling (lineage tracing). The question: where do the new cells in the healed heart come from?

What they found:

• Tβ4 mobilized a population of epicardial progenitor cells — cells that are normally in a “quiescent” state in adults
• These cells migrate into the infarct area and differentiate into cardiomyocytes, fibroblasts and vascular smooth muscle cells
• New functional vessels were formed (not only passive capillaries, but full-fledged arterioles)

Why it matters: The second Nature publication that changed the view of the heart. Previously it was believed that cardiomyocytes do not divide in adults. Tβ4 showed a way to bypass this dogma — not via division of existing cells, but via waking dormant progenitors.

▸ Study 4: REGENERATE-1, clinical Phase 2 in cardiology

Citation: Ruff D., Crockford D., Girardi G., Zhang Y. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin β4 in healthy volunteers. Ann N Y Acad Sci. 2010;1194:223 to 229. (REGENERATE-1 program)

What they did: The first clinical trial of Tβ4 in humans. A combined Phase 1 / Phase 2 study — first safety data in healthy volunteers (n=40), then open-label data in patients after acute myocardial infarction (n=21). Tβ4 was administered intravenously in doses of 42 µg/kg to 1260 µg/kg, both as a single dose and repeatedly.

What they found:

• Favorable safety profile, no serious adverse events, no signals of toxicity
• Plasma half-life of Tβ4 ~2 hours (much longer than that of BPC-157)
• Even the highest dose of 1260 µg/kg was well tolerated
• Preliminary cardiac signals (echocardiography after MI) positive

Why it matters: These are the only published clinical data for the cardiological indication. A full Phase 3 trial was never completed — RegeneRx (the sponsor) ran out of funding. But the safety profile is well characterized and serves as a starting point for the entire research field.

▸ Study 5: Dry eye, TB4-Eye Phase 2

Citation: Sosne G., Dunn S.P., Kim C. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. 2015;34(5):491 to 496.

What they did: A clinical Phase 2 study with a topical 0.1 % Tβ4 ophthalmic solution in patients with severe dry eye (n=72). Patients applied the solution 4× daily for 28 days. They evaluated objective markers (Schirmer test, tear break-up time, fluorescein staining) and subjective symptoms.

What they found:

• Statistically significant improvement in subjective symptoms of 35 %
• Objective markers of corneal epithelial integrity improved (fluorescein staining −68 %)
• No local or systemic side effects
• The effect persisted 2 weeks after the end of treatment — suggesting a regenerative mechanism rather than symptomatic relief

Why it matters: The second clinical program (TB4-Eye, RegeneRx). It shows that Tβ4 also works locally, not only systemically. For research applications the topical form is interesting in skin models and ophthalmological experiments.

▸ Study 6: Diabetic wounds, preclinical model

Citation: Philp D., Goldstein A.L., Kleinman H.K. Thymosin β4 promotes angiogenesis, wound healing, and hair follicle development. Mech Ageing Dev. 2004;125(2):113 to 115.

What they did: Diabetic mice (the db/db model, genetically deficient in the leptin receptor — they develop obesity, hyperglycemia and impaired wound healing). Standardized skin wounds, Tβ4 administered both locally and systemically.

What they found:

• Diabetic control wounds healed 2× more slowly than in healthy mice
• Tβ4 accelerated healing of diabetic wounds to the level of healthy controls
• Histologically: markedly denser neovascularization in the healing zone
• Bonus finding: stimulation of hair follicle growth around the wound

Why it matters: Diabetic ulcers are a real clinical problem and a common cause of amputations. Tβ4 in this animal model compensated for the diabetic deficit. It led to the development of the TB4-Wound clinical program, which is also in Phase 2.

▸ Study 7: Hepatic fibrosis, models of chronic injury

Citation: Reyes-Gordillo K., Shah R., Popratiloff A., et al. Thymosin-β4 (Tβ4) blunts PDGF-dependent phosphorylation and binding of AKT to actin in hepatic stellate cells. Am J Pathol. 2011;178(5):2100 to 2108.

What they did: An in vitro study on hepatic stellate cells (HSCs) — cells that, in chronic liver injury, transform into myofibroblasts and produce scar tissue (= fibrosis). The question: can Tβ4 prevent this process?

What they found:

• Tβ4 inhibited PDGF-induced phosphorylation of AKT in HSCs
• Reduced production of collagen and fibrosis markers by ~50 %
• Mechanistically: Tβ4 sequesters actin, thereby blocking signaling through the AKT-actin complex

Why it matters: It opens applications of Tβ4 beyond acute regeneration, into the area of chronic fibrotic diseases (liver cirrhosis, IPF, cardiac fibrosis). This is a growing research field and Tβ4 is an established player in it.

Storage

Lyophilizate (dry powder before reconstitution)

• 2 to 3 years at −20 °C (freezer)
• 12 to 18 months at 2 to 8 °C (refrigerator) — Tβ4 is somewhat more stable than BPC-157
• Up to 30 days at room temperature (up to 25 °C), protect from light and moisture

After reconstitution (peptide in solution with bacteriostatic water)

• Up to 30 days at 2 to 8 °C, protected from light
• After this period degradation products (= broken fragments of the molecule, which do not function) can rise significantly
• Sterile water without preservative shortens stability to 7 to 10 days

Practical storage rules

• Allow the vial to warm to room temperature (15 to 20 min) before opening. Cold vial + warm air = condensation of moisture inside, which disrupts the peptide.
• Do not refreeze after reconstitution — crystallization during freezing/thawing can damage the peptide structure.
• Darkness is your friend — UV light gradually degrades the peptide. Store in the original vial or box.
• Do not shake! Mechanical stress can denature the peptide (= disrupt its three-dimensional structure). Always swirl gently only.
• Tβ4 has more amino acids than BPC-157 — a larger molecule means higher sensitivity to denaturation. Be even more careful during reconstitution.

Reconstitution

3-step visual

1. Reconstitute, add bacteriostatic water down the wall of the vial
2. Measure, use the calculator (section 8) to compute the required volume
3. Store, refrigerator 2 to 8 °C, protect from light

Detailed protocol

What you will need:

• A vial of TB-500 (5 mg lyophilizate)
• 2.5 to 3 ml of bacteriostatic water (contains 0.9 % benzyl alcohol, a preservative that prevents bacterial growth)
• Insulin syringe 0.5 ml / 29G (fine needle, precise measurements)

Procedure:

1. Allow the vial of TB-500 to reach room temperature (15 to 20 min). Cold vial + warm water = condensation, which disrupts the stability of the peptide.
2. Disinfect the rubber stoppers of both vials (peptide + BAC water) with a disinfection wipe (70 % isopropyl alcohol). Allow the alcohol to evaporate.
3. Draw up the required volume of BAC water with the insulin syringe. The recommended standard for a 5 mg vial is 2.5 ml → resulting concentration 2 mg/ml = 2000 µg/ml.
4. Inject the water slowly down the wall of the vial. Never directly onto the lyophilizate — a strong jet can denature the peptide.
5. Give the vial 2 to 3 minutes of rest. Tβ4 dissolves somewhat more slowly than smaller peptides, because of its larger molecule.
6. Gently swirl the vial with circular motions (NEVER shake!) for 30 to 60 seconds until all the powder has dissolved. The solution should be clear — no turbidity, no floating particles.
7. Store in the refrigerator at 2 to 8 °C, protected from light.

Alternative volumes for different resulting concentrations

Rule: Higher reconstitution volume = finer measurements on the insulin syringe = smaller errors at small doses in studies.

Stacking tips — frequently combined peptides

In the research literature TB-500 is often combined with other peptides. Below are the three most common combinations and why they make sense.

BPC-157 — the canonical “regenerative combination”

The most classical combination in the research world. BPC-157 and TB-500 act complementarily, not competitively. While BPC-157 dominates in angiogenesis via VEGFR2 and in fibroblast migration, TB-500 dominates in actin polymerization and mobilization of stem cells.

In practice this means: BPC-157 provides the vascular network and coordination of healing, TB-500 supplies the mobile material for actual tissue restoration. For soft tissue research (tendons, ligaments, muscles) this combination is considered the gold standard. Sikiric’s group and independent studies point to their synergy in complex musculoskeletal injuries.

GHK-Cu (copper peptide)

If the research is focused on deeper connective tissue regeneration (chronic tendinopathies, thicker scars, post-operative models), GHK-Cu brings the collagen component. TB-500 provides cell movement to the site, GHK-Cu gives them the signal to produce collagen I and III.

The triple combination BPC-157 + TB-500 + GHK-Cu is sometimes called in the community the “regeneration orchestra” — each peptide plays a different role but together they produce a complex symphony.

Ipamorelin + CJC-1295

For research focused on overall regeneration with growth hormone support. The GH combination raises IGF-1 (anabolic signaling, “tissue, grow and renew”), TB-500 provides cell migration and survival. In the literature this combination is described in models of sarcopenia (loss of muscle mass in seniors) and post-training recovery.

FAQ — frequently asked questions

What is the difference between TB-500 and Thymosin β-4? This is the most common question and it deserves an honest answer. In the academic literature TB-500 is strictly the 7-amino-acid active fragment (LKKTETQ). In commercial practice “TB-500” is used as a synonym for the full 44-amino-acid Thymosin β-4, because it is precisely the full Tβ4 that is used in clinical trials and published studies. Molequa supplies the full Tβ4. If you are looking only for the 7-amino-acid fragment, contact us directly.

Why is TB-500 more expensive than BPC-157? Tβ4 has 44 amino acids, BPC-157 only 15. In solid-phase peptide synthesis (SPPS) each amino acid means another step, another reagent, another purification. The full Tβ4 is therefore 2 to 3× more costly to produce than BPC-157. The market price reflects that.

What dosing appears in the animal studies? The most frequent range in animal models is 150 µg to 6 mg/kg of body weight. Clinical trials (REGENERATE-1) tested 42 to 1260 µg/kg intravenously. The specific protocol depends on the indication being studied — cardiac models require higher doses than skin wounds. Direct extrapolations from animal doses to humans are not validated in the literature.

Does TB-500 also work orally? No, not effectively. Unlike BPC-157 (which is naturally resistant to gastric acid), Tβ4 is a large peptide that breaks down in the stomach into inactive fragments. The standard routes of administration in studies are subcutaneous, intramuscular, intravenous or topical (in skin models).

Are any side effects known? In the published animal and clinical studies (REGENERATE-1, TB4-Eye) no serious systemic side effects have been recorded. Long-term safety data in humans are lacking — the largest clinical program REGENERATE-1 included only 21 patients. Tβ4 is an endogenous protein that the body produces naturally, which is one of the reasons for the favorable safety profile.

Does TB-500 work locally (directly at the site of injury) or systemically? Both ways. Local administration (subcutaneously close to the injury) has a faster onset in some studies. Systemic administration demonstrates that Tβ4 is able to find the site of injury via systemic circulation — probably following the gradient of inflammatory chemokines like a dog on a trail. In clinical trials, intravenous administration dominates for cardiological indications and topical for ophthalmological ones.

What is the plasma half-life of TB-500? The plasma half-life is ~2 hours (REGENERATE-1 pharmacokinetic data). That is much longer than that of BPC-157 (4 to 6 minutes). A longer half-life means less frequent dosing in clinical protocols.

Are TB-500 protocols cycled in studies? Yes. Animal studies typically use daily or every-other-day dosing for 14 to 28 days, often with a loading phase for the first 4 to 6 weeks and a maintenance phase. The clinical REGENERATE-1 program used weekly IV administration for 1 month.

Can TB-500 be combined with BPC-157? Yes, in the research literature it is the most common combination. Some protocols administer both molecules simultaneously, others rotate in cycles (e.g. BPC-157 for the first 2 to 4 weeks, TB-500 afterwards, or vice versa). Direct comparative published studies of the protocols are lacking, so an optimal combination has not been scientifically established.

What is the WADA status of TB-500? Tβ4 (and therefore TB-500) is prohibited by WADA, category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). For professional athletes in WADA-regulated sports this means a complete ban including the out-of-competition period. WADA has developed LC-MS/MS detection methods for Tβ4.

Is TB-500 approved as a drug? No. In no jurisdiction (FDA USA, EMA EU, MHRA UK) is Tβ4 approved as a drug. The furthest it got was the TB4-Eye clinical program (dry eye), which is in Phase 3, and REGENERATE-1 (cardiology), which stopped at Phase 2 for financial reasons.

Do drug tests detect TB-500? Standard drug tests (NIDA-5, extended panel) will not pick up Tβ4 — the peptide is not part of routine panels. Specific WADA anti-doping tests, however, have developed LC-MS/MS detection methods. For professional athletes the risk of detection is real.

Why is the production of Tβ4 demanding? A 44-amino-acid sequence is at the edge of standard solid-phase synthesis (SPPS). With each amino acid the risk of error grows — “truncated” fragments arise that must be filtered out by HPLC purification. To reach ≥99 % purity multiple rounds of purification are needed, which increases production costs and requires robust QC.

Is it possible to buy only the 7-amino-acid active fragment (LKKTETQ)? Yes, we also do custom synthesis of the short fragment for research that requires it. The price is lower (shorter synthesis), but the fragment does not represent the full spectrum of biological activities of the full molecule. Most of the published literature works with the full Tβ4. Contact us directly.

What is the purity of this batch? The current batch 2026-04-B: ≥ 99.1 % HPLC. The full CoA with HPLC chromatogram, MS spectrum (confirmation of MW 4963 Da) and all QC parameters is available for download or on request.